STING1 and neoplasm: A novel vaccine composed of cyclic GMP-AMP (cGAMP) (a STING agonist) and adsorbed tumor-associated antigens was developed to activate the STING pathway, enhancing the efficacy of immunotherapy and significantly preventing the recurrence and metastasis of HCC (58) (Table 2).